Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?
- 23 December 2016
- journal article
- review article
- Published by Radcliffe Media Media Ltd in European Cardiology Review
- Vol. 11 (2), 115-117
- https://doi.org/10.15420/ecr.2016.11.2.ed2
Abstract
Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?This publication has 18 references indexed in Scilit:
- Evaluation of Dose-Reduced Direct Oral Anticoagulant TherapyThe American Journal of Medicine, 2016
- Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort studyBMJ, 2016
- Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?American Journal of Cardiovascular Drugs, 2016
- Andexanet Alfa for the Reversal of Factor Xa Inhibitor ActivityThe New England Journal of Medicine, 2015
- Idarucizumab for Dabigatran ReversalThe New England Journal of Medicine, 2015
- Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking RivaroxabanClinical Cardiology, 2015
- Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial FibrillationCirculation, 2015
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial FibrillationJournal of the American College of Cardiology, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2013
- Identifying Patients at High Risk for Stroke Despite AnticoagulationStroke, 2010